Roche Doubles Down On SCLC By In-Licensing MediLink’s ADC

 
• By Dexter Jie Yan
  
lung cancer
MediLink's YL201 is currently being evaluated in a China-only Phase III clinical trial in ES-SCLC in a second-line setting. • Source: Shutterstock

More from Deals

More from Business